vs
NEOGEN CORP（NEOG）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
NEOGEN CORP的季度营收约是STURM RUGER & CO INC的1.5倍（$224.7M vs $151.1M），STURM RUGER & CO INC同比增速更快（3.6% vs -2.8%），STURM RUGER & CO INC自由现金流更多（$12.3M vs $7.8M），过去两年STURM RUGER & CO INC的营收复合增速更高（5.1% vs -0.9%）
Neogen Corporation是一家1982年成立、总部位于美国密歇根州兰辛的跨国食品安全企业，专注提供各类检测试剂盒及相关产品，用于筛查食品中的有害成分。目前业务覆盖美国、加拿大、英国、欧洲部分地区、墨西哥、巴西、印度、中国等多个国家，旗下拥有超100款药物检测试剂盒产品，可检测约300种相关违禁物质。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
NEOG vs RGR — 直观对比
营收规模更大
NEOG
是对方的1.5倍
$151.1M
营收增速更快
RGR
高出6.5%
-2.8%
自由现金流更多
RGR
多$4.6M
$7.8M
两年增速更快
RGR
近两年复合增速
-0.9%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $224.7M | $151.1M |
| 净利润 | $-15.9M | — |
| 毛利率 | 47.5% | 17.8% |
| 营业利润率 | -2.4% | 2.3% |
| 净利率 | -7.1% | — |
| 营收同比 | -2.8% | 3.6% |
| 净利润同比 | 96.5% | — |
| 每股收益（稀释后） | $-0.07 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NEOGRGR
| Q4 25 | $224.7M | $151.1M | ||
| Q3 25 | $209.2M | $126.8M | ||
| Q2 25 | $225.4M | $132.5M | ||
| Q1 25 | $221.0M | $135.7M | ||
| Q4 24 | $231.3M | $145.8M | ||
| Q3 24 | $217.0M | $122.3M | ||
| Q2 24 | $236.8M | $130.8M | ||
| Q1 24 | $228.8M | $136.8M |
净利润NEOGRGR
| Q4 25 | $-15.9M | — | ||
| Q3 25 | $36.3M | $1.6M | ||
| Q2 25 | $-612.3M | $-17.2M | ||
| Q1 25 | $-10.9M | $7.8M | ||
| Q4 24 | $-456.3M | — | ||
| Q3 24 | $-12.6M | $4.7M | ||
| Q2 24 | $-5.4M | $8.3M | ||
| Q1 24 | $-2.0M | $7.1M |
毛利率NEOGRGR
| Q4 25 | 47.5% | 17.8% | ||
| Q3 25 | 45.4% | 15.1% | ||
| Q2 25 | 41.2% | 3.9% | ||
| Q1 25 | 49.9% | 22.0% | ||
| Q4 24 | 49.0% | 22.8% | ||
| Q3 24 | 48.4% | 18.5% | ||
| Q2 24 | 47.9% | 22.3% | ||
| Q1 24 | 51.1% | 21.5% |
营业利润率NEOGRGR
| Q4 25 | -2.4% | 2.3% | ||
| Q3 25 | -7.7% | -2.7% | ||
| Q2 25 | -271.1% | -15.6% | ||
| Q1 25 | 2.4% | 6.2% | ||
| Q4 24 | -197.8% | 7.8% | ||
| Q3 24 | 1.0% | 3.1% | ||
| Q2 24 | 5.5% | 6.9% | ||
| Q1 24 | 5.3% | 5.5% |
净利率NEOGRGR
| Q4 25 | -7.1% | — | ||
| Q3 25 | 17.4% | 1.2% | ||
| Q2 25 | -271.6% | -13.0% | ||
| Q1 25 | -4.9% | 5.7% | ||
| Q4 24 | -197.3% | — | ||
| Q3 24 | -5.8% | 3.9% | ||
| Q2 24 | -2.3% | 6.3% | ||
| Q1 24 | -0.9% | 5.2% |
每股收益（稀释后）NEOGRGR
| Q4 25 | $-0.07 | $0.22 | ||
| Q3 25 | $0.17 | $0.10 | ||
| Q2 25 | $-2.82 | $-1.05 | ||
| Q1 25 | $-0.05 | $0.46 | ||
| Q4 24 | $-2.10 | $0.62 | ||
| Q3 24 | $-0.06 | $0.28 | ||
| Q2 24 | $-0.02 | $0.47 | ||
| Q1 24 | $-0.01 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $145.3M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $283.8M |
| 总资产 | $3.4B | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NEOGRGR
| Q4 25 | $145.3M | $92.5M | ||
| Q3 25 | $138.9M | $80.8M | ||
| Q2 25 | $129.0M | $101.4M | ||
| Q1 25 | $127.7M | $108.3M | ||
| Q4 24 | $140.2M | $105.5M | ||
| Q3 24 | $120.5M | $96.0M | ||
| Q2 24 | $170.9M | $105.6M | ||
| Q1 24 | $168.4M | $115.3M |
股东权益NEOGRGR
| Q4 25 | $2.1B | $283.8M | ||
| Q3 25 | $2.1B | $279.6M | ||
| Q2 25 | $2.1B | $289.3M | ||
| Q1 25 | $2.7B | $321.5M | ||
| Q4 24 | $2.7B | $319.6M | ||
| Q3 24 | $3.1B | $314.9M | ||
| Q2 24 | $3.1B | $321.5M | ||
| Q1 24 | $3.1B | $332.0M |
总资产NEOGRGR
| Q4 25 | $3.4B | $342.0M | ||
| Q3 25 | $3.4B | $342.3M | ||
| Q2 25 | $3.4B | $349.5M | ||
| Q1 25 | $4.0B | $379.0M | ||
| Q4 24 | $4.1B | $384.0M | ||
| Q3 24 | $4.5B | $373.5M | ||
| Q2 24 | $4.5B | $376.7M | ||
| Q1 24 | $4.6B | $385.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.4M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $7.8M | $12.3M |
| 自由现金流率自由现金流/营收 | 3.5% | 8.2% |
| 资本支出强度资本支出/营收 | 5.2% | 2.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-18.5M | $38.5M |
8季度趋势，按日历期对齐
经营现金流NEOGRGR
| Q4 25 | $19.4M | $15.5M | ||
| Q3 25 | $10.9M | $12.9M | ||
| Q2 25 | $16.4M | $14.7M | ||
| Q1 25 | $19.5M | $11.1M | ||
| Q4 24 | $40.3M | $20.0M | ||
| Q3 24 | $-17.9M | $9.4M | ||
| Q2 24 | $26.7M | $18.7M | ||
| Q1 24 | $-30.2M | $7.3M |
自由现金流NEOGRGR
| Q4 25 | $7.8M | $12.3M | ||
| Q3 25 | $-13.1M | $7.0M | ||
| Q2 25 | $349.0K | $9.1M | ||
| Q1 25 | $-13.4M | $10.0M | ||
| Q4 24 | $23.1M | $16.4M | ||
| Q3 24 | $-56.3M | $2.6M | ||
| Q2 24 | $2.5M | $10.1M | ||
| Q1 24 | $-62.3M | $5.6M |
自由现金流率NEOGRGR
| Q4 25 | 3.5% | 8.2% | ||
| Q3 25 | -6.3% | 5.5% | ||
| Q2 25 | 0.2% | 6.9% | ||
| Q1 25 | -6.1% | 7.4% | ||
| Q4 24 | 10.0% | 11.2% | ||
| Q3 24 | -26.0% | 2.1% | ||
| Q2 24 | 1.1% | 7.7% | ||
| Q1 24 | -27.2% | 4.1% |
资本支出强度NEOGRGR
| Q4 25 | 5.2% | 2.1% | ||
| Q3 25 | 11.5% | 4.6% | ||
| Q2 25 | 7.1% | 4.2% | ||
| Q1 25 | 14.9% | 0.8% | ||
| Q4 24 | 7.4% | 2.5% | ||
| Q3 24 | 17.7% | 5.5% | ||
| Q2 24 | 10.2% | 6.6% | ||
| Q1 24 | 14.0% | 1.3% |
现金转化率NEOGRGR
| Q4 25 | — | — | ||
| Q3 25 | 0.30× | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NEOG
| Other | $109.2M | 49% |
| Bacterial And General Sanitation | $44.9M | 20% |
| Services | $25.7M | 11% |
| Natural Toxins And Allergens | $20.4M | 9% |
| Animal Care | $8.9M | 4% |
| Genomics Services | $6.3M | 3% |
| Biosecurity Products | $4.6M | 2% |
| Life Sciences | $1.4M | 1% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
